Mazziotta, Francesco
 Distribuzione geografica
Continente #
NA - Nord America 732
EU - Europa 311
AS - Asia 142
AF - Africa 46
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 1
Totale 1.237
Nazione #
US - Stati Uniti d'America 716
SE - Svezia 131
IT - Italia 87
CN - Cina 75
SG - Singapore 40
BG - Bulgaria 37
CI - Costa d'Avorio 28
FR - Francia 21
NG - Nigeria 17
CA - Canada 16
VN - Vietnam 15
DE - Germania 9
GB - Regno Unito 9
HK - Hong Kong 6
RU - Federazione Russa 6
AU - Australia 5
CZ - Repubblica Ceca 2
ES - Italia 2
IN - India 2
JP - Giappone 2
TR - Turchia 2
ET - Etiopia 1
EU - Europa 1
FI - Finlandia 1
GR - Grecia 1
IE - Irlanda 1
NL - Olanda 1
PL - Polonia 1
RO - Romania 1
UA - Ucraina 1
Totale 1.237
Città #
Chandler 114
Woodbridge 83
Fairfield 76
Ashburn 49
Houston 49
Beijing 40
Seattle 40
Sofia 37
Serra 32
Wilmington 30
Cambridge 29
New York 29
Abidjan 28
Boardman 22
Princeton 20
Florence 19
Lagos 17
Lawrence 17
Medford 14
Ottawa 14
Ann Arbor 12
Des Moines 12
Singapore 11
Dong Ket 7
Bremen 6
Dearborn 6
Hong Kong 6
Hebei 5
London 5
Pisa 5
San Diego 5
Sydney 5
Boulder 4
Changsha 4
Jiaxing 4
San Jose 4
Kunming 3
Livorno 3
Nanchang 3
Nanjing 3
Palermo 3
Shenyang 3
Brno 2
Capannori 2
Kilburn 2
Los Angeles 2
Ogden 2
Rome 2
Santa Clara 2
Santa Maria A Monte 2
Washington 2
Addis Ababa 1
Almere Stad 1
Arezzo 1
Bandra 1
Baotou 1
Carrara 1
Cedar Knolls 1
Chicago 1
Cincinnati 1
Dallas 1
Delaware 1
Hefei 1
Helsinki 1
Jinan 1
Jinhua 1
Kocaeli 1
Massa 1
Ningbo 1
North York 1
Palo Alto 1
Paris 1
Phoenix 1
Redwood City 1
San Francisco 1
Tokyo 1
Toronto 1
Tullamore 1
Turin 1
Vinci 1
Wandsworth 1
Warsaw 1
Totale 927
Nome #
Mesangiogenic progenitor cells are forced toward the angiogenic fate, in multiple myeloma 105
The combination of rituximab and bendamustine as first-line treatment is highly effective in the eradicating minimal residual disease in follicular lymphoma: An Italian retrospective study 100
The WNT pathway is relevant for the BCR-ABL1-independent resistance in chronic myeloid leukemia 98
ACUTE T-LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC T-CELL LYMPHOMA. ROLE OF EARLY allo-SCT 95
The onset of monoclonal and oligoclonal gammopathies is a good prognostic factor after allogeneic stem cell transplantation 88
The Onset of Monoclonal and Oligoclonal Gammopathies Is a Good Prognostic Factor after Allogeneic Stem Cell Transplantation 87
Immune Reconstitution after Allogeneic Stem Cell Transplantation: a Pilot Flow-Cytometry Study for T-Cell Sub-Populations 85
Plasma Cell Disorders and Dialysis-Dependent Renal Failure: Safety and Efficacy of Autologous Stem Cell Transplantation 76
The assessment of minimal residual disease versus that of somatic mutations for predicting the outcome of acute myeloid leukemia patients 74
The Minimal Residual Disease in Non-Hodgkin's Lymphomas: From the Laboratory to the Clinical Practice 71
Safety and Efficacy of Rituximab and Cyclophosphamide in a Case of Resistant Acquired Hemophilia A in Course of Chronic Lymphocytic Leukemia 67
Cytokine Release from Stimulated PBMC after-HSCT: Results of a Post-Transplant Zinc Oral Supplementation Trial (ZENITH). 64
AUTOLOGOUS-STEM CELL TRANSPLANTATION IN DIFFUSE-LARGE B CELL LYMPHOMA: THE TUSCANY EXPERIENCE 62
ACUTE T-LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC T-CELL LYMPHOMA. ROLE OF EARLY allo-SCT 61
AUTOLOGOUS-STEM CELL TRANSPLANTATION IN HODGKIN'S LYMPHOMA: THE TUSCANY EXPERIENCE 58
Activation of the Zinc-sensing receptor GPR39 promotes T cell reconstitution after hematopoietic cell transplant in mice 53
Joint Pain and Arthritis as First Clinical Manifestation of Systemic Amyloidosis and Multiple Myeloma: Case Report and Brief Literature Review 24
Totale 1.268
Categoria #
all - tutte 4.541
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.541


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020227 0 0 0 12 21 39 48 26 27 21 28 5
2020/2021117 8 6 4 4 8 13 0 4 16 9 21 24
2021/2022184 7 6 2 10 31 23 2 3 12 9 17 62
2022/2023360 47 65 24 31 43 33 5 32 49 3 26 2
2023/2024141 8 12 25 3 13 31 10 5 2 3 8 21
2024/202530 1 18 9 2 0 0 0 0 0 0 0 0
Totale 1.268